ObesityRoche and Zealand’s obesity contender clears phase 2, but investors were looking for moreRoche and Zealand Pharma have delivered a clinically positive phase 2 readout for petrelintide, their amylin-based obesity drug, but the market reaction made clear that “positive” is no longer enough … more ➔
M&AAlfasigma bets up to $690M on GSK’s late-stage PBC itch drug ahead of FDA decisionItalian drugmaker Alfasigma has struck a licensing deal to take over global rights to linerixibat, GSK’s late-stage candidate for cholestatic pruritus in primary biliary cholangitis (PBC), in a transaction … more ➔
Unsplash+M&AServier buys Day One for $2.5bn to bolster its rare cancer pipelineFrench pharma giant Servier is spending US$2.5bn to snap up Day One Biopharmaceuticals, gaining a key approved drug for difficult childhood brain tumours along with several promising pipeline candid … more ➔
Startupskyron.bio teams up with Servier to test “precision glycosylation” as a new lever for antibody performanceParis-based kyron.bio has signed a strategic partnership with French pharma group Servier to glycoengineer an antibody selected by Servier. This agreement marks an early proof-of-concept deal designed … more ➔
Molecular Partners AG & NuMeRI, presentation Feb. 2026RadiopharmaceuticalsRadioligands give Molecular Partners new momentum in a market already at full speedThe Zurich-based developer is increasingly focusing its pipeline on radiopharmaceutical cancer therapies. A recent development agreement with isotope specialist Eckert & Ziegler marks another step in … more ➔
BispecificUCB licenses Antengene’s ATG-201 in $1.1B autoimmune masked T-cell engager dealUCB is adding a new kind of immune-cell weapon to its immunology arsenal. The Belgian biopharma said it has struck a global licensing deal with Hong Kong–based Antengene for ATG-201, a CD19/CD3 bispecific … more ➔
LicensingBoehringer steps back from MASH programm as OSE restructure its pipelineFrench biotech OSE Immunotherapeutics is narrowing its ambitions to just two late-stage programs after a one–two hit: AbbVie backing away from an inflammation partnership and Boehringer Ingelheim halting … more ➔
Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, GermanyRealtime ImagingNVision visualizes metabolics at work and expands to the Cambridge Innovation ClusterQuantum computers? While most people have heard that their massively parallel data processing could open up an entirely new dimension of information technology, tangible real-world examples remain scarce. … more ➔
Sitryx TherapeuticsImmunologySitryx adds another BigPharma and partners with Boehringer Ingelheim in autoimmune pushOxford-based immunology specialist Sitryx has entered into a new agreement with Boehringer Ingelheim aimed at advancing a novel small-molecule programme in autoimmune and inflammatory disease. The deal … more ➔
M&AJapan’s Asahi Kasei buys antiviral specialist Aicuris in €780 million dealTakeover in Wuppertal: Aicuris Anti-Infective Cures AG, which specializes in active ingredients for infectious diseases, is being acquired by Japanese pharmaceutical company Asahi Kasei for almost €800 … more ➔
Unsplash+
Molecular Partners AG & NuMeRI, presentation Feb. 2026
Courtesy Luca Nagel, Department of Nuclear Medicine, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany
Sitryx Therapeutics
